ストックスクリーナーアプリを入手
0.9495
5.99%
-0.0605
前日終値:
$1.01
開ける：
$1
24時間の取引高:
46,793
Relative Volume:
0.36
時価総額：
$39.90M
収益：
-
当期純損益:
$-31.37M
株価収益率:
-0.6603
EPS:
-1.438
ネットキャッシュフロー:
$-4.23M
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
-10.42%
6か月 パフォーマンス:
-35.84%
1年 パフォーマンス:
-23.73%
1日の値動き範囲:
$0.9402
$1.00
1週間の範囲:
$0.902
$1.01
52週間の値動き範囲:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.9495 | 42.44M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,229.93 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.31 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.38 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.59 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView
K6S Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Flat at Open - Baystreet.ca
MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com
Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus
Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia
MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks
MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan
MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire
MIRA Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mira Pharmaceuticals Inc (MIRA) Institutional Confidence - TradingKey
Mira Pharmaceuticals Inc (MIRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mira Pharmaceuticals Inc (MIRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Pharmaceuticals submits Phase 2a trial for Ketamir-2 - grafa.com
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN - Investing.com UK
MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial - TipRanks
Phase 2a CIPN trial protocol for Ketamir-2 accepted, MIRA (NASDAQ: MIRA) - Stock Titan
Chemo nerve damage leaves millions without an approved drug; MIRA plans Ketamir-2 trial - Stock Titan
Mira Pharmaceuticals Submits Phase 2a Trial Protocol for Ketamir-2 to FDA - Moomoo
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award - Stock Titan
MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94 - Stock Titan
MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options - Stock Titan
MIRA Pharmaceuticals Inc. (MIRA) Edges Higher: Navigating Key Levels in a Volatile SectorGolden Cross - newsline.com
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - The Globe and Mail
MIRA PHARMACEUTICALS (MIRA) CFO Andriy Mushak listed as insider in Form 3 - Stock Titan
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Nigeria
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com
Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
MIRA appoints Andriy Mushak as fractional CFO as Alan Weichselbaum departs - TradingView
Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM - Stock Titan
Mira Pharmaceuticals Inc (MIRA) 財務データ
収益
当期純利益
現金流量
EPS
0.33%
1.21%
大文字化:
|
ボリューム (24 時間):